President Donald Trump signed an executive order directing the FDA to expedite its review of psychedelic-based treatments for severe mental health conditions, with a sharp focus on veterans suffering from PTSD, traumatic brain injuries, and depression. The move pairs new federal research dollars with a clear message: the bureaucratic bottleneck standing between wounded veterans and promising therapies has gone on long enough.

Trump announced the order Saturday morning after teasing it to reporters aboard Air Force One the previous day. The signing drew an unusual coalition of supporters, from former Texas Governor Rick Perry to podcast host Joe Rogan, who was present at the event, and immediately drew praise from veterans' advocacy groups that have spent years pushing for access to treatments the federal government still classifies alongside heroin.

The order targets drugs already designated as breakthrough therapies and in advanced clinical trials, including psilocybin, ibogaine, LSD, and MDMA. It directs the FDA to clear what Trump called "unnecessary bureaucratic hurdles," improve data sharing between the FDA and the Department of Veterans Affairs, and facilitate fast rescheduling of any psychedelic drugs that eventually win FDA approval.

A $50 million bet on ibogaine

The executive order carries a price tag. Trump announced a new $50 million federal research investment in ibogaine, a psychoactive compound derived from the root of a shrub native to Central Africa, matching a previously cited $50 million commitment from Texas Republican leaders, Fox News reported. The combined $100 million would represent the most significant government-backed push to study the compound's potential for treating brain injuries and PTSD in military veterans.

Ibogaine currently sits on the Drug Enforcement Administration's Schedule I list, meaning the federal government considers it to have no accepted medical use and a high potential for abuse. That classification puts it in the same category as heroin and ecstasy. Drug classifications are divided into five schedules, with Schedule I carrying the highest restrictions.

But a growing body of research suggests the classification may be outdated. A Stanford Medicine study released in 2024 concluded that ibogaine effectively treated military veterans with traumatic brain injuries. Nolan Williams, an associate professor of behavioral sciences and psychiatry involved in the research, did not mince words about what the data showed.

"No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury. The results are dramatic, and we intend to study this compound further."

That finding helped build momentum for the executive action. The order also creates a pathway for ibogaine to be included in the Right to Try framework, which allows terminally ill patients to access experimental treatments that have not yet received full FDA approval. Trump specifically mentioned ibogaine during his remarks, Breitbart reported.

Veterans at the center

The administration framed the order squarely around the veteran suicide and mental health crisis. Trump told the audience that the treatments in question have shown real potential for people suffering from severe mental illness, depression, and PTSD, "especially for veterans," as he put it.

The president's language was direct. "We're taking this decision, this decisive step, to confront one of the most urgent public health challenges facing our nation, the mental health crisis," Trump said. He added: "Today's order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life."

Veterans Affairs Secretary Doug Collins endorsed the move, telling reporters that the VA needs every available tool. "We need an all-of-the-above strategy when it comes to tackling mental health, and your EO opens up new possibilities for America's Veterans," Collins said, as the Washington Examiner reported.

The reaction from advocacy groups was immediate. Amber Capone, CEO and founder of Veterans Exploring Treatment Solutions, told Reuters the news marked a "huge sigh of relief" for the community that has watched veterans seek treatment abroad because the drugs remain restricted in the United States. Ibogaine is unregulated in Mexico, the Netherlands, Germany, and Canada, meaning American veterans who want to try it have had to leave the country.

Capone's full statement captured the frustration of advocates who have long believed the evidence was there, even if the federal bureaucracy refused to act on it:

"There's no doubt whatsoever in our minds that it works. But we just can't say, 'Believe us.' The research has to corroborate what we know to be true, and it feels like we could finally, finally be making some impact."

Perry, Rogan, and a growing coalition

The executive order did not materialize overnight. Former Texas Governor Rick Perry, who served as Energy Secretary under Trump's first administration, helped launch the nonprofit Americans for Ibogaine last year. The organization's stated mission is to advance education, clinical research, and responsible medical access to the drug. Perry and the group's CEO, W. Bryan Hubbard, appeared on The Joe Rogan Experience last month to advocate for ibogaine, a media appearance that brought the issue to a massive audience outside traditional policy circles.

The administration has not been shy about framing its executive actions as decisive wins, and the psychedelic order fits that pattern. Trump described the people behind the push as "very good, very smart, very caring" and called the broader effort a "very positive thing", language that signals the White House sees political upside in championing an issue that cuts across traditional ideological lines.

The order also builds on a prior executive action. In December, Trump signed an executive order paving the way for medical applications of marijuana and CBD products, the Daily Mail reported. That earlier move signaled the administration's willingness to challenge longstanding federal drug classifications when the medical evidence pointed in a different direction.

What the order does, and what it doesn't

The executive order does not reschedule any drug. It does not legalize psilocybin, ibogaine, or MDMA for recreational use. What it does is direct the FDA to move faster on treatments that have already cleared significant clinical hurdles and earned breakthrough therapy designations, a formal FDA label that is supposed to speed development and review of drugs addressing serious conditions.

The order also improves data sharing between the FDA and the VA, which advocates have long identified as a bottleneck. Veterans participating in clinical trials at VA facilities generate data that the FDA needs to evaluate treatments, but interagency coordination has been slow and inconsistent. The new directive aims to fix that.

For conservatives who value limited government and individual liberty, the Right to Try angle may be the most significant piece. By opening a pathway for ibogaine under that framework, the administration is saying that veterans and other patients with severe conditions should not have to wait years for a federal agency to finish its review process before they can access treatments their doctors believe may help them.

That principle, that the government should not stand between a patient and a promising treatment, is one the right has championed for years. The political opposition may find it difficult to argue against an order that pairs fiscal responsibility with compassion for wounded veterans.

The real cost of delay

The veterans who stand to benefit from this order have not had the luxury of waiting for Washington to catch up. Many have traveled to Mexico or the Netherlands to receive ibogaine treatment out of pocket, outside any regulated medical system, because the DEA's Schedule I classification made domestic research and access nearly impossible.

That is the cost of bureaucratic inertia: not just delayed paperwork, but Americans leaving the country to seek treatment for injuries they sustained in service to it. The Stanford study's findings, that no other drug has matched ibogaine's results for traumatic brain injury symptoms, make the federal government's decades-long inaction harder to defend with each passing year.

The administration's broader political strategy clearly includes building a record of concrete action on issues that matter to the base and beyond. An executive order that funds research, cuts red tape, and puts veterans first is hard to oppose on substance, which may explain why the loudest objections so far have been about process rather than principle.

Trump spoke aboard Air Force One on Friday about the issue, telling reporters he felt "strongly about" the subject before teasing the Saturday announcement. The White House has faced legal and political resistance on other fronts, but on psychedelic research for veterans, the coalition of support runs from former governors to military families to medical researchers.

Open questions remain

The executive order sets a direction, but several questions remain unanswered. Which federal agencies beyond the FDA and VA will be responsible for implementing the new research guidance? How quickly will the $50 million in federal funds be allocated, and through what grant mechanisms? Will the DEA move to reschedule ibogaine or psilocybin if the FDA approves them, or will that require a separate fight?

The text of the executive order itself has not been publicly released in full. And while the order directs faster review, the FDA retains its authority over approval decisions. An executive order can change priorities and timelines. It cannot change the science. The clinical trials still have to produce the results.

But for veterans who have spent years watching Washington debate while they suffered, the order represents something concrete: a commander in chief willing to act on evidence that the permanent bureaucracy has been content to study indefinitely.

When the people who fought for this country have to fly to Mexico for treatment, the problem is not the science. The problem is the system.